Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $6.4 million.

  • Traws Pharma's Cash & Equivalents rose 1866.91% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 1866.91%. This contributed to the annual value of $21.3 million for FY2024, which is 248.31% up from last year.
  • Per Traws Pharma's latest filing, its Cash & Equivalents stood at $6.4 million for Q3 2025, which was up 1866.91% from $13.1 million recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Cash & Equivalents registered a high of $59.4 million during Q3 2021, and its lowest value of $5.4 million during Q3 2024.
  • For the 5-year period, Traws Pharma's Cash & Equivalents averaged around $31.1 million, with its median value being $29.7 million (2023).
  • Per our database at Business Quant, Traws Pharma's Cash & Equivalents skyrocketed by 18946.12% in 2021 and then tumbled by 7856.92% in 2024.
  • Quarter analysis of 5 years shows Traws Pharma's Cash & Equivalents stood at $55.1 million in 2021, then decreased by 29.62% to $38.8 million in 2022, then crashed by 46.28% to $20.8 million in 2023, then grew by 2.48% to $21.3 million in 2024, then tumbled by 69.91% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $13.1 million for Q2 2025, and $15.9 million during Q1 2025.